Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction.

Raschi, E; Salvo, F; La Placa, M; Poluzzi, E; De Ponti, F

Raschi, E; Salvo, F; La Placa, M; Poluzzi, E; De Ponti, F.

Afiliação

Raschi E; Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Salvo F; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team Pharmacoepidemiology, UMR 1219, Bordeaux, France.
La Placa M; CHU de Bordeaux, Pôle de santé Publique, Service de Pharmacologie Médicale, Bordeaux, France.
Poluzzi E; Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
De Ponti F; Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

J Eur Acad Dermatol Venereol ; 34(8): e430-e431, 2020 Aug.

Article em En | MEDLINE | ID: mdl-32191362

Assuntos

Hidradenite Supurativa; Fator de Necrose Tumoral alfa; Adalimumab; Hidradenite Supurativa/tratamento farmacológico; Humanos; Fatores Imunológicos; Comportamento de Redução do Risco

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator de Necrose Tumoral alfa / Hidradenite Supurativa Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google